AlphAIAlphAI — Financial news for AI agents
seekingalpha.comNOV 21 min read$BMRN

BioMarin Pharmaceutical Non-GAAP EPS of $0.23 beats by $0.34, revenue of $1.03B beats by $10M (BMRN:NASDAQ)

BioMarin Pharmaceutical reported Q3 Non-GAAP EPS of $0.23, exceeding estimates by $0.34. Revenue reached $1.03B, up 32.7% year-over-year and $10M above expectations. Growth was driven by a 44% increase in metabolic conditions revenue and a 12% rise in skeletal revenue.

Original reporting
seekingalpha.com
Published Nov 2, 2026, 9:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 9:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$BMRN
Bullish
high confidence
Mentioned
$BMRN
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$BMRNBullishHigh
01

Why it matters

The earnings beat is likely to lift BMRN's share price in the immediate trading session.

02

Market read

First‑report earnings beat for a mid‑cap biotech, providing a clear catalyst for short‑term trading.

03

What to watch

Guidance for Q4 and pipeline updates are not disclosed, which could temper upside.

Relevance 8/10Novelty 8/10Timing: after‑hours release

Background

BioMarin released its Q3 2026 earnings, highlighting a 32% YoY revenue increase driven by metabolic and skeletal product lines.

Company-level read

Ticker impact

$BMRNBullishHigh confidence
Context

Q3 2026 Non‑GAAP EPS of $0.23 beats expectations by $0.34 and revenue of $1.03 B beats by $10 M.

Expected impact

upward pressure as the market prices in the earnings beat.

Evidence & confidence

Both EPS and revenue exceeded expectations, indicating stronger performance than forecast.

Market effects

Sector

Biotech sector may see modest uplift as a peer reports strong results.

Regional

U.S. biotech stocks could benefit from the positive earnings surprise.

Global

Limited to investors tracking biotech earnings; no broader macro impact.

Counterpoint

What could challenge this read

If the beat is already priced in, the stock could face short‑term profit‑taking.

Key entities

  • company
    BioMarin Pharmaceutical Inc.

    U.S. biotech firm reporting Q3 2026 results.

Read at source← All news

StoryBioMarin posts Q3 2026 revenue above $1 billion but trims full‑year outlook

Also covered by

4 outlets

Related articles

NOV 3
$BMRNHighAI 8/10

BioMarin reports Q3 revenue beat but cuts full-year outlook

BioMarin Pharmaceutical (BMRN) reported Q3 revenue of $1.025B, beating estimates. EPS matched expectations at $0.23. The company lowered full-year revenue guidance by $50M and fiscal 2026 earnings guidance to $2.80-$3.10 per share, citing delays in Voxzogo orders and business development impacts. Management expects faster cost synergies from the Amicus acquisition.

investing.com2 min
NOV 3
$BMRNHighAI 8/10

BioMarin (BMRN) Q3 2026 Earnings Call Transcript

BioMarin (BMRN) reported Q3 2026 revenue growth of 44% in metabolic conditions, driven by Galafold, Pombility, and Opfolda, which generated over $200M combined. VOXZOGO saw a 17% increase in treated patients. The company updated guidance, citing order timing and geopolitical headwinds, and highlighted pipeline advancements like BMN-450 for Fabry disease. Galafold revenue was $152M, up 10% YoY, while Pombility and Opfolda revenue was $49M, up 58% YoY.

finance.yahoo.com3 min
NOV 3
$BMRNMedAI 8/10

BioMarin Pharmaceutical Q3 Earnings Call Highlights

BioMarin (BMRN) reported Q3 earnings, with Voxzogo revenue up 12% YoY to $245M. The company lowered 2026 revenue guidance to $3.8B-$3.9B due to order timing and regional disruptions. Non-GAAP EPS guidance is $2.80-$3.10, including impacts from recent acquisitions. BioMarin also provided updates on its pipeline, including BMN 450 for Fabry disease and BMN 440 for hypophosphatasia.

finance.yahoo.com3 min
NOV 2
$BMRNMedAI 8/10

BioMarin: Q3 Earnings Snapshot

BioMarin Pharmaceutical Inc. reported a Q3 loss of $122.8 million, or 63 cents per share, but adjusted earnings of 23 cents per share beat expectations. Revenue of $1.02 billion missed forecasts. The company expects full-year earnings of $2.80 to $3.10 per share and revenue of $3.8 billion to $3.9 billion. Shares are down 3% YTD but up 7% over 12 months.

finance.yahoo.com2 min